Boston Scientific Corporation (LON:0HOY)

London flag London · Delayed Price · Currency is GBP · Price in USD
45.40
-0.20 (-0.43%)
Jul 31, 2026, 5:06 PM GMT
Market Cap51.60B -56.6%
Revenue (ttm)15.82B +13.5%
Net Income2.77B +46.6%
EPS1.86 +46.9%
Shares Out n/a
PE Ratio18.63
Forward PE14.30
Dividendn/a
Ex-Dividend Daten/a
Volume16,145
Open46.04
Previous Close45.60
Day's Range44.48 - 46.48
52-Week Range41.58 - 109.51
Beta0.58
Analystsn/a
Price Targetn/a
Earnings DateJul 29, 2026

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]

Sector Healthcare
Founded 1979
Employees 59,000
Stock Exchange London Stock Exchange
Ticker Symbol 0HOY

Financial Performance

In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.

Financial numbers in USD Financial Statements

News

Argus cuts Boston Scientific to Hold on growth headwinds

As previously reported, Argus downgraded Boston Scientific (BSX) to Hold from Buy. The firm notes that the company faces headwinds to growth and key product platforms, including Watchman and electroph...

1 day ago - TheFly

Boston Scientific downgraded to Hold from Buy at Argus

Argus downgraded Boston Scientific (BSX) to Hold from Buy.

1 day ago - TheFly

Penumbra reports Q2 EPS 88c, consensus $1.18

Reports Q2 revenue $390M, consensus $390.08M. Given the pending acquisition of Penumbra (PEN) by Boston Scientific (BSX), the company will not be providing financial guidance for the full year 2026…

2 days ago - TheFly

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

2 days ago - PRNewsWire

Boston Scientific price target lowered to $70 from $85 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Boston Scientific (BSX) to $70 from $85 and keeps an Outperform rating on the shares. The company reported a…

2 days ago - TheFly

Boston Scientific price target lowered to $56 from $80 at JPMorgan

JPMorgan lowered the firm’s price target on Boston Scientific (BSX) to $56 from $80 and keeps an Overweight rating on the shares.

2 days ago - TheFly

Boston Scientific price target lowered to $54 from $61 at BofA

BofA lowered the firm’s price target on Boston Scientific (BSX) to $54 from $61 and keeps a Buy rating on the shares. For 2027, the firm models 3% revenue growth…

2 days ago - TheFly

Boston Scientific price target lowered to $67 from $74 at UBS

UBS lowered the firm’s price target on Boston Scientific (BSX) to $67 from $74 and keeps a Buy rating on the shares.

2 days ago - TheFly

Boston Scientific price target lowered to $55 from $65 at Evercore ISI

Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $55 from $65 and keeps an Outperform rating on the shares.

2 days ago - TheFly

Boston Scientific price target lowered to $60 from $75 at Deutsche Bank

Deutsche Bank analyst Pito Chickering lowered the firm’s price target on Boston Scientific (BSX) to $60 from $75 and keeps a Buy rating on the shares.

2 days ago - TheFly

Boston Scientific price target lowered to $56 from $64 at Baird

Baird lowered the firm’s price target on Boston Scientific (BSX) to $56 from $64 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results…

2 days ago - TheFly

Boston Scientific price target lowered to $56 from $61 at TD Cowen

TD Cowen lowered the firm’s price target on Boston Scientific (BSX) to $56 from $61 and keeps a Buy rating on the shares. The firm said though solid 7% organic…

2 days ago - TheFly

Boston Scientific price target lowered to $66 from $70 at Canaccord

Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $66 from $70 and keeps a Buy rating on the shares. The firm said Management again cut guidance for…

2 days ago - TheFly

Boston Scientific price target lowered to $60 from $74 at Leerink

Leerink lowered the firm’s price target on Boston Scientific (BSX) to $60 from $74 and keeps an Outperform rating on the shares.

2 days ago - TheFly

Boston Scientific price target lowered to $50 from $55 at Wells Fargo

Wells Fargo lowered the firm’s price target on Boston Scientific (BSX) to $50 from $55 and keeps an Equal Weight rating on the shares. The firm notes reported a Q2…

2 days ago - TheFly

Boston Scientific price target lowered to $61 from $70 at Citi

Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $61 from $70 and keeps a Buy rating on the shares. The firm updated the company’s…

2 days ago - TheFly

Boston Scientific price target lowered to $60 from $65 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Boston Scientific (BSX) to $60 from $65 and keeps a Buy rating on the shares. The latest round of guidance…

3 days ago - TheFly

Boston Scientific Earnings Call Transcript: Q2 2026

Q2 2026 saw 7% organic sales growth and 15% adjusted EPS growth, exceeding guidance. Full-year 2026 outlook was revised down due to WATCHMAN and EP headwinds, with organic revenue now expected to grow 5%-6% and adjusted EPS 7%-8%. Restructuring and new launches are set to drive recovery by 2028.

3 days ago - Transcripts

Boston Scientific Slides: Q2 2026

Boston Scientific has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.

3 days ago - Filings

Boston Scientific Earnings release: Q2 2026

Boston Scientific released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.

3 days ago - Filings

Boston Scientific Cuts Outlook Ahead of Restructuring

Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.

3 days ago - WSJ

Boston Scientific trims annual profit forecast on softer Watchman device demand

Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.

3 days ago - Reuters

Boston Scientific sees Q3 adjusted EPS 80c-82c, consensus 84c

Sees Q3 revenue up 3%-5%. The company said, “The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to…

3 days ago - TheFly

Boston Scientific cuts FY26 adjusted EPS view to $3.28-$3.32 from $3.34-$3.41

Consensus $3.36. Cuts FY26 revenue view to up 5.5%-6.5% from up 7%-8.5%. The company said, “The company now estimates net sales growth for the full year 2026, versus the prior…

3 days ago - TheFly

Boston Scientific announces results for second quarter 2026

MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported b...

3 days ago - PRNewsWire